id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-276013-8dhqa2gj	Luo, Yung-Hung	Overview of coronavirus disease 2019: Treatment updates and advances	2020-08-17		.txt	text/plain	3764	232	47	7, 11 Patients with severe symptoms may have unfavorable disease Abstract: In late December 2019, several cases of pneumonia with unknown cause were reported in Wuhan, China, and this new type of pneumonia spread rapidly to across provinces during the subsequent weeks. Clinical trials on baricitinib demonstrated at least some effects in selective patient populations with COVID-19 acute respiratory disease. On March 17, 2020, the National Medical Products Administration of China approved favipiravir as the first coronavirus drug with evidence from clinical trials showing efficacy for the treatment of COVID-19 infection. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)	./cache/cord-276013-8dhqa2gj.txt	./txt/cord-276013-8dhqa2gj.txt